Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy
- 31 March 2003
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 39 (5), 631-634
- https://doi.org/10.1016/s0959-8049(02)00745-1
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Adenovirus-mediated human topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cellsActa Oncologica, 2005
- Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the MessageJournal of Clinical Oncology, 2001
- Chromogenic in Situ Hybridization: A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer SamplesThe American Journal of Pathology, 2000
- Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast CancerThe American Journal of Pathology, 2000
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.Proceedings of the National Academy of Sciences of the United States of America, 1993
- ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.Proceedings of the National Academy of Sciences of the United States of America, 1992
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.Molecular and Cellular Biology, 1986
- Reporting results of cancer treatmentCancer, 1981